"A vaccine capable of inducing an effective antibody response against amyloid-beta toxic oligomers (ABOs) could be administered prophylactically to at-risk individuals to prevent development of symptomatic disease," the release noted. Toxic oligomers have been implicated in the development of neurodegenerative diseases, including Alzheimer's, the company noted.
Also, ProMIS indicated that the vaccine could be used to inhibit disease progression in people with an Alzheimer's diagnosis.
The University of Saskatchewan's Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) will start the vaccine development process by generating multivalent vaccine constructs based on ProMIS peptides linked to a carrier protein. It will incorporate an adjuvant to maximally induce a protective antibody response to ABOs. VIDO-InterVac is a global leader in vaccine research, development and commercialization.
Previously, ProMIS reported that it had identified in a proof-of-concept study six different peptide epitopes that were selectively exposed on toxic ABOs. When mice were injected with each epitope, they produced protective antibodies against ABOs with no occurrence of adverse binding to amyloid-beta monomers or fibrils.
In addition, ProMIS noted that it also conducted a successful proof-of-concept vaccination study using one of the peptide epitopes in a mouse model of Alzheimer's disease. That showed the peptide epitope protected neurons and improved cognitive deficits.
Read what other experts are saying about:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.